Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

101885

registered interest
date	30/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dementia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when his Department will publish guidance on the timeline for a successor to the National Dementia Strategy for England and the Prime Minister's Challenge on Dementia.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	212582
answer	answer is ministerial correction date of answer 06/11/2014 answer text <p>The Department has established a new time-limited Stakeholder Advisory Group to help inform the next phase of work on dementia, post the current Prime Minister’s Challenge on Dementia, which superseded the National Dementia Strategy and which is due to end in March 2015.</p><p> </p><p> </p><p> </p><p>The Advisory Group is providing advice to help inform the Department’s work to shape the future direction of domestic dementia policy to 2020. The group met for the first time on 17 October to discuss their draft terms of reference for the proposed work programme and timeline.</p><p> </p><p> </p><p> </p><p>Once finalised the terms of reference for the group and other details including the envisaged timeline for the work will be published on the Department of Health’s Prime Ministers Challenge website.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 212685 question first answered 06/11/2014 13:31:29 answering member 1439 label Biography information for Norman Lamb
tabling member	4022 label Biography information for Oliver Colvile

101912

registered interest
date	30/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dementia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when his Department expects to announce the timetable for developing a successor strategy to the National Dementia Strategy for England and the Prime Minister's Challenge on Dementia.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	212685
answer	answer is ministerial correction date of answer 06/11/2014 answer text <p>The Department has established a new time-limited Stakeholder Advisory Group to help inform the next phase of work on dementia, post the current Prime Minister’s Challenge on Dementia, which superseded the National Dementia Strategy and which is due to end in March 2015.</p><p> </p><p> </p><p> </p><p>The Advisory Group is providing advice to help inform the Department’s work to shape the future direction of domestic dementia policy to 2020. The group met for the first time on 17 October to discuss their draft terms of reference for the proposed work programme and timeline.</p><p> </p><p> </p><p> </p><p>Once finalised the terms of reference for the group and other details including the envisaged timeline for the work will be published on the Department of Health’s Prime Ministers Challenge website.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 212582 question first answered 06/11/2014 13:31:29 answering member 1439 label Biography information for Norman Lamb
tabling member	4022 label Biography information for Oliver Colvile

101915

registered interest
date	30/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dementia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what detailed assessments he has made of the effectiveness of the National Dementia Strategy; and if he will publish the full results of that assessment.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	212686
answer	answer is ministerial correction date of answer 06/11/2014 answer text <p>While the Department has not undertaken a detailed assessment of the effectiveness of the National Dementia Strategy, it has commissioned an independent assessment of the improvements in dementia care and support since 2009, which incorporates the progress made under both the National Dementia Strategy (2009-14) and the current Prime Minister’s Challenge on Dementia. The National Dementia Strategy was superseded by the Prime Minister's Challenge on Dementia launched in 2012, which builds on and takes forward at pace the work commenced as part of the National Dementia Strategy. The Prime Minister's Challenge concludes at the end of March 2015.</p><p> </p><p> </p><p> </p><p>The National Dementia Strategy has been the subject of more detailed work by the All Party Parliamentary Group (APPG) on Dementia and other organisations this year, which is being used to inform the Department’s work on the future of dementia care and support. The APPG published a report in May 2014, ‘Building on the National Dementia Strategy: Change, progress and priorities’.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 212671 question first answered 06/11/2014 15:27:13 answering member 1439 label Biography information for Norman Lamb
tabling member	4022 label Biography information for Oliver Colvile

101923

registered interest
date	30/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dementia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether an official review of the National Dementia Strategy has taken place.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	212671
answer	answer is ministerial correction date of answer 06/11/2014 answer text <p>While the Department has not undertaken a detailed assessment of the effectiveness of the National Dementia Strategy, it has commissioned an independent assessment of the improvements in dementia care and support since 2009, which incorporates the progress made under both the National Dementia Strategy (2009-14) and the current Prime Minister’s Challenge on Dementia. The National Dementia Strategy was superseded by the Prime Minister's Challenge on Dementia launched in 2012, which builds on and takes forward at pace the work commenced as part of the National Dementia Strategy. The Prime Minister's Challenge concludes at the end of March 2015.</p><p> </p><p> </p><p> </p><p>The National Dementia Strategy has been the subject of more detailed work by the All Party Parliamentary Group (APPG) on Dementia and other organisations this year, which is being used to inform the Department’s work on the future of dementia care and support. The APPG published a report in May 2014, ‘Building on the National Dementia Strategy: Change, progress and priorities’.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 212686 question first answered 06/11/2014 15:27:13 answering member 1439 label Biography information for Norman Lamb
tabling member	4022 label Biography information for Oliver Colvile

92616

registered interest
date	10/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hip Replacements
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many hip replacement operations were conducted in (a) Devon and Cornwall and (b) England in (i) 2013 and (ii) 2014.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	209295
answer	answer is ministerial correction date of answer 20/10/2014 answer text <p>In the following table, we have provided information concerning the number of finished consultant episodes (FCEs)<sup>1</sup> with a main or secondary procedure<sup>2</sup> of hip replacement<sup>3</sup> in Devon, Cornwall and Isles of Scilly Area Team of Treatment, and England.</p><p> </p><p> </p><p> </p><p>Data for 2013-14 is currently provisional and will be published once it has been validated.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Devon, Cornwall and Isles of Scilly Area Team of Treatment</p></td><td><p>England</p></td></tr><tr><td><p>2012-13</p></td><td><p>5,311</p></td><td><p>105,499</p></td></tr></tbody></table><p> </p><p>Activity in English NHS Hospitals and English NHS commissioned activity in the independent sector</p><p> </p><p><strong> </strong></p><p> </p><p><em>Notes:</em></p><p> </p><p>1. A finished consultant episode (FCE) is a continuous period of admitted patient care under one consultant within one healthcare provider. FCEs are counted against the year in which they end. Figures do not represent the number of different patients, as a person may have more than one episode of care within the same stay in hospital or in different stays in the same year.</p><p> </p><p>2. The number of episodes where the procedure (or intervention) was recorded in any of the 24 (12 from 2002-03 to 2006-07 and 4 prior to 2002-03) procedure fields in a Hospital Episode Statistics (HES) record. A record is only included once in each count, even if the procedure is recorded in more than one procedure field of the record. Note that more procedures are carried out than episodes with a main or secondary procedure.</p><p> </p><p>3. Coding used includes replacements, revisions and conversions of both hip replacements and hemiarthroplasty.</p><p> </p><p> </p><p> </p><p><em>Source:</em> Hospital Episode Statistics (HES), Health and Social Care Information Centre</p><p><strong><br> </strong></p> answering member constituency Battersea answering member printed Jane Ellison question first answered 20/10/2014 17:38:05 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

76803

registered interest
date	09/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Care Act 2014
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will include forming and developing relationship in the eligibility criteria of the Care Act 2014 Part 1 regulations.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	204705
answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The Care Act 2014 will introduce a modern system thatwill promote and maintain the wellbeing of people who have care and support needs and support them in living independent lives. These enhance the areas of action set out in the 2010 Autism Strategy and reaffirmed recently in <em>Think Autism</em>.</p><p>The Care Act includes a power to make regulations to set the national eligibility criteria for adult care and support. The national eligibility threshold will provide a similar level of access to care and support when we move from the current system to the reformed system in April 2015.</p><p> </p><p>The Department is currently consulting on the draft regulations and statutory guidance that will support the implementation of the Care Act. This includes the draft eligibility regulations which set the level of the threshold, and your comments will be considered when we finalise and publish the regulations in October. The public consultation started on 6 June and runs until 15 August 2014.</p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 14/07/2014 14:55:28 answering member 1439 label Biography information for Norman Lamb
tabling member	4022 label Biography information for Oliver Colvile

64761

registered interest
date	30/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmacy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that the expertise of community pharmacists is fully utilised to reduce the burden on general practice.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	203013
answer	answer is ministerial correction date of answer 03/07/2014 answer text <p>Pharmacy already plays a vital role in supporting the health of people in their local communities, providing high quality care and support, improving people's health and reducing health inequalities. As we move to more integrated care, there is real potential for pharmacists and their teams to play an even greater role in the future, particularly in keeping people healthy, supporting those with long-term conditions and helping make sure patients and the National Health Service get the best use from medicines.</p><p> </p><p>The Department and NHS England's publication <em>Transforming Primary Care - Safe, proactive, personalised care for those who need it most</em>, sets out plans for more proactive, personalised and joined up care, part of which is harnessing the potential of pharmacists. This recognises the vital role that pharmacists have in optimising medicines use, helping to prevent avoidable hospital admissions and supporting people to manage their own care. A copy has already been placed in the Library.</p><p> </p><p>NHS England's public consultation, <em>Improving care through community pharmacy –</em> <em>a call to action</em>, has provided an important opportunity to explore the contribution community pharmacists and their teams can make. This will inform a strategic framework for commissioning wider primary care services in the autumn, including consideration of fully utilising the expertise of community pharmacists in reducing burdens on other health services, such as general practice. A copy of the consultation document is at:</p><p> </p><p>www.england.nhs.uk/ourwork/qual-clin-lead/calltoaction/pharm-cta/</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 03/07/2014 13:24:28 answering member 1439 label Biography information for Norman Lamb
tabling member	4022 label Biography information for Oliver Colvile

64765

registered interest
date	30/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmacy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects to be able to introduce the sharing of patient data with community pharmacists in support of patient safety in England.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	203009
answer	answer is ministerial correction date of answer 03/07/2014 answer text <p>Local solutions are presently being developed. In addition, NHS England has commissioned the Health and Social Care Information Centre to deliver a “proof of concept” project in order to enable 80-100 community pharmacies, across 2 or 3 geographical areas, to access the Summary Care Record (SCR). Subject to the proof of concept, the SCR should provide a platform which will enable pharmacists and pharmacy technicians to view prescribed medicines, allergies and adverse reactions for patients who go to their pharmacy for urgent or unscheduled care.</p><p> </p><p>The project aims to:</p><p> </p><p>- determine if SCR viewing can be safely implemented in community pharmacies and will add value to existing practice and patients' experience by improving quality, safety and continuity of care;</p><p>- identify the optimum model for implementation should the proof of concept conclude that SCR access provides added value; and</p><p>- assess whether providing community pharmacies with access to the SCR has the potential to relieve the increasing demands on the wider healthcare system.</p><p> </p><p>It is planned that the first pharmacies will go live towards the end of 2014, with the project due to provide its findings and recommendations early in 2015. Further plans will be developed based on those findings and will be published in due course.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 03/07/2014 13:20:15 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	4022 label Biography information for Oliver Colvile

58515

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what treatments for prostate cancer are routinely funded by NHS England.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199303
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199302 199304 question first answered 10/06/2014 15:28:10 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

58516

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of outcomes for men with advanced prostate cancer.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199304
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199302 199303 question first answered 10/06/2014 15:28:11 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile